预防顺铂诱发的成人听力损失:系统回顾与元分析》。

IF 1.9 3区 医学 Q3 CLINICAL NEUROLOGY
Otology & Neurotology Pub Date : 2025-04-01 Epub Date: 2025-02-04 DOI:10.1097/MAO.0000000000004446
Erin E Briggs, Ethan M Kallenberger, Shaun A Nguyen, Peter R Dixon, Allyson V Drawdy, Alexandra E Kejner, John M Kaczmar, Jason G Newman, W Greer Albergotti
{"title":"预防顺铂诱发的成人听力损失:系统回顾与元分析》。","authors":"Erin E Briggs, Ethan M Kallenberger, Shaun A Nguyen, Peter R Dixon, Allyson V Drawdy, Alexandra E Kejner, John M Kaczmar, Jason G Newman, W Greer Albergotti","doi":"10.1097/MAO.0000000000004446","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Ototoxicity is a known side effect of cisplatin chemotherapy. The efficacy of various medications used to prevent or reduce ototoxicity in adults receiving cisplatin has not been thoroughly described in the literature.</p><p><strong>Data sources: </strong>CINAHL, Cochrane Library, PubMed, and SCOPUS.</p><p><strong>Review methods: </strong>Literature was searched between 1990 and 2024. Studies evaluating interventions to prevent hearing loss in adults receiving cisplatin were included. Audiometric data including pure tone threshold, pure tone average, and incidence of hearing loss were extracted from included studies.</p><p><strong>Results: </strong>Eight studies (N = 431 total patients) pertaining to cisplatin-induced hearing loss in adults were included. Of these studies, six were randomized control trials (N = 372 patients) and two were prospective cohort studies (N = 59 patients). The cytoprotective treatments included diethyldithiocarbamate (intravenously), dexamethasone (intratympanic), N -acetylcysteine (intratympanic), sodium thiosulfate (intravenously), calcium gluconate (intravenously), and aspirin (PO). The treatment group had an incidence in overall hearing loss of 63.3% compared to the 66.2% incidence in the control group ([95% CI, -6.2 to 11.9] p = 0.53). Patients treated with dexamethasone had lower degrees of hearing loss compared to those treated with N -acetylcysteine. However, neither of these interventions were superior to the control group.</p><p><strong>Conclusions: </strong>These results show no difference in reducing the incidence nor severity of hearing loss between the treatment and control groups. Standardization of evaluated frequencies and ototoxicity grading scales will improve investigators' ability to compare various treatments. Unfortunately, the power of this study is limited by the sample size.</p>","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":" ","pages":"351-357"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preventing Cisplatin-Induced Hearing Loss in Adults: A Systematic Review and Meta-Analysis.\",\"authors\":\"Erin E Briggs, Ethan M Kallenberger, Shaun A Nguyen, Peter R Dixon, Allyson V Drawdy, Alexandra E Kejner, John M Kaczmar, Jason G Newman, W Greer Albergotti\",\"doi\":\"10.1097/MAO.0000000000004446\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Ototoxicity is a known side effect of cisplatin chemotherapy. The efficacy of various medications used to prevent or reduce ototoxicity in adults receiving cisplatin has not been thoroughly described in the literature.</p><p><strong>Data sources: </strong>CINAHL, Cochrane Library, PubMed, and SCOPUS.</p><p><strong>Review methods: </strong>Literature was searched between 1990 and 2024. Studies evaluating interventions to prevent hearing loss in adults receiving cisplatin were included. Audiometric data including pure tone threshold, pure tone average, and incidence of hearing loss were extracted from included studies.</p><p><strong>Results: </strong>Eight studies (N = 431 total patients) pertaining to cisplatin-induced hearing loss in adults were included. Of these studies, six were randomized control trials (N = 372 patients) and two were prospective cohort studies (N = 59 patients). The cytoprotective treatments included diethyldithiocarbamate (intravenously), dexamethasone (intratympanic), N -acetylcysteine (intratympanic), sodium thiosulfate (intravenously), calcium gluconate (intravenously), and aspirin (PO). The treatment group had an incidence in overall hearing loss of 63.3% compared to the 66.2% incidence in the control group ([95% CI, -6.2 to 11.9] p = 0.53). Patients treated with dexamethasone had lower degrees of hearing loss compared to those treated with N -acetylcysteine. However, neither of these interventions were superior to the control group.</p><p><strong>Conclusions: </strong>These results show no difference in reducing the incidence nor severity of hearing loss between the treatment and control groups. Standardization of evaluated frequencies and ototoxicity grading scales will improve investigators' ability to compare various treatments. Unfortunately, the power of this study is limited by the sample size.</p>\",\"PeriodicalId\":19732,\"journal\":{\"name\":\"Otology & Neurotology\",\"volume\":\" \",\"pages\":\"351-357\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Otology & Neurotology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MAO.0000000000004446\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Otology & Neurotology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MAO.0000000000004446","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:耳毒性是已知的顺铂化疗副作用。在接受顺铂治疗的成人中,用于预防或减少耳毒性的各种药物的疗效尚未在文献中得到彻底的描述。数据来源:CINAHL, Cochrane Library, PubMed, SCOPUS。回顾方法:检索1990 - 2024年间的文献。研究评估干预措施,以防止听力损失的成人接受顺铂纳入。从纳入的研究中提取听力测量数据,包括纯音阈值、纯音平均值和听力损失发生率。结果:8项研究(N = 431例患者)涉及成人顺铂诱导的听力损失。其中6项为随机对照试验(N = 372例),2项为前瞻性队列研究(N = 59例)。细胞保护治疗包括二乙基二硫代氨基甲酸酯(静脉注射)、地塞米松(鼓室注射)、n -乙酰半胱氨酸(鼓室注射)、硫代硫酸钠(静脉注射)、葡萄糖酸钙(静脉注射)和阿司匹林(PO)。治疗组总体听力损失发生率为63.3%,对照组为66.2% ([95% CI, -6.2 ~ 11.9] p = 0.53)。用地塞米松治疗的患者与用n -乙酰半胱氨酸治疗的患者相比,听力损失程度较低。然而,这两种干预措施都没有优于对照组。结论:这些结果显示治疗组和对照组在降低听力损失的发生率和严重程度方面没有差异。评估频率和耳毒性分级量表的标准化将提高研究者比较各种治疗方法的能力。不幸的是,这项研究的力量受到样本量的限制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Preventing Cisplatin-Induced Hearing Loss in Adults: A Systematic Review and Meta-Analysis.

Objective: Ototoxicity is a known side effect of cisplatin chemotherapy. The efficacy of various medications used to prevent or reduce ototoxicity in adults receiving cisplatin has not been thoroughly described in the literature.

Data sources: CINAHL, Cochrane Library, PubMed, and SCOPUS.

Review methods: Literature was searched between 1990 and 2024. Studies evaluating interventions to prevent hearing loss in adults receiving cisplatin were included. Audiometric data including pure tone threshold, pure tone average, and incidence of hearing loss were extracted from included studies.

Results: Eight studies (N = 431 total patients) pertaining to cisplatin-induced hearing loss in adults were included. Of these studies, six were randomized control trials (N = 372 patients) and two were prospective cohort studies (N = 59 patients). The cytoprotective treatments included diethyldithiocarbamate (intravenously), dexamethasone (intratympanic), N -acetylcysteine (intratympanic), sodium thiosulfate (intravenously), calcium gluconate (intravenously), and aspirin (PO). The treatment group had an incidence in overall hearing loss of 63.3% compared to the 66.2% incidence in the control group ([95% CI, -6.2 to 11.9] p = 0.53). Patients treated with dexamethasone had lower degrees of hearing loss compared to those treated with N -acetylcysteine. However, neither of these interventions were superior to the control group.

Conclusions: These results show no difference in reducing the incidence nor severity of hearing loss between the treatment and control groups. Standardization of evaluated frequencies and ototoxicity grading scales will improve investigators' ability to compare various treatments. Unfortunately, the power of this study is limited by the sample size.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Otology & Neurotology
Otology & Neurotology 医学-耳鼻喉科学
CiteScore
3.80
自引率
14.30%
发文量
509
审稿时长
3-6 weeks
期刊介绍: ​​​​​Otology & Neurotology publishes original articles relating to both clinical and basic science aspects of otology, neurotology, and cranial base surgery. As the foremost journal in its field, it has become the favored place for publishing the best of new science relating to the human ear and its diseases. The broadly international character of its contributing authors, editorial board, and readership provides the Journal its decidedly global perspective.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信